The breadth of family medicine in one meeting

My wife and I returned last night from the annual Family Medicine Education Consortium meeting, which was held in Atlantic City this year. Despite the rainy weather, it was an enjoyable conference. I presented the latest evidence on multicancer blood tests, which are limited and imperfect tools that family doctors should think twice about ordering for their patients even if Galleri is approved by the U.S. Food and Drug Administration. Plenary speakers included family physician and YouTube sensation Mike Varshavski, DO, better known as Doctor Mike. Over two packed days, I was only able to sample a small slice of the 400+ presentations (including posters) by Northeast family medicine faculty, residents, and medical students. Nonetheless, these demonstrate the tremendous clinical and policy breadth of the specialty of family medicine. To show that breadth, and for the curious who want to know what sorts of talks I gravitate to at a conference like this, here are the topics of the oral presentations I attended:

Shaping the future of size-inclusive care: lessons from a medical student elective

Continuous glucose monitor utilization for insulin-dependent patients in family medicine clinic

A mixed-methods evaluation of Pennsylvania IMPLICIT Network sites

A 40-year retrospective cohort study of primary care alumni of NEOMED

Beyond statins

The Pap stops here: cervical cancer screening for women with HIV

From PCE to PREVENT: rethinking CVD risk in family medicine

This is our lane: building confidence in firearm storage safety conversations with patients

Primary care for all Americans: the current evidence and the plan to fix

Joint hypermobility in family medicine

An integrative approach to metabolic syndrome

Enhancing your research workflow with artificial intelligence

Shaping the future of care: where leadership, policy, and AI converge

When ideology dictates science policy: Trofim Lysenko and Robert F. Kennedy, Jr.

30 years ago, I took a college class on the history of Russian and Soviet science. One of the more infamous figures in an otherwise accomplished pantheon of scientists was a man named Trofim Lysenko, who rejected Mendelian genetics and espoused a form of agricultural pseudoscience. In a naturally self-correcting scientific system, he should have been an historical footnote, but by cleverly aligning his theories with Marxist ideology and ingratiating himself with Joseph Stalin, he managed to hold on to power for decades, at the expense of thousands of legitimate scientists and the Soviet people who depended on successful crop yields to feed their families.

Trofim Lysenko

Studying Lysenko, I would have been shocked if I had known that history would repeat itself in the United States, where a similar figure would promote thoroughly debunked theories about childhood vaccines and elevate his ideology above science at every turn. Thanks to elections and Presidential term limits, Robert F. Kennedy Jr.'s reign as the head of the U.S. Department of Health and Human Services (HHS) is likely to be much shorter than Lysenko's in the Soviet Union. However, the damage he has done to our scientific institutions and the scourge of preventable infectious diseases he has unleashed may take many more years to be repaired.

Robert F. Kennedy, Jr.

I am not the first person to compare the HHS Secretary's actions to those of Lysenko, but I don't believe there is a more definitive treatment of this analogy than my perspective article in the Fall 2026 issue of the Journal of Lancaster General Hospital.

e-Cigarettes for tobacco smoking cessation

Although e-cigarettes are generally considered to be less harmful than combustible cigarettes, whether vaping should be explicitly incorporated into tobacco smoking cessation strategies is controversial. In 2021, the US Preventive Services Task Force (USPSTF) found insufficient evidence to determine the balance of benefits and harms of e-cigarettes for smoking cessation in adults. At that time, the USPSTF cited a lack of well-designed, randomized controlled trials (RCTs) that reported smoking abstinence and adverse events. Other concerns included potential effects of e-cigarette promotion on already high rates of e-cigarette initiation in children and adolescents.

Subsequent studies have supported the utility of e-cigarettes for smoking cessation. A Swiss RCT that compared e-cigarettes to usual care cessation strategies (counseling and medications) found that the e-cigarette group was more likely to be abstinent from tobacco at 6 months (number needed to treat [NNT] = 6-8); adverse events were similar between groups. A Cochrane review of 88 studies, including 47 RCTs, found high-certainty evidence that e-cigarettes increased smoking cessation at 6 months to 1 year compared to nicotine replacement therapy (NRT) and other smoking cessation treatments. e-Cigarettes were associated with a similar incidence of adverse events to NRT and more adverse events than counseling (number needed to harm [NNH] = 7). Serious adverse events were not increased in the e-cigarette groups. Another RCT in persons of low socioeconomic status found that vaping nicotine was more effective than NRT for achieving tobacco abstinence at 6 months (NNT = 5).

A working group of the international Society for Research on Nicotine and Tobacco recently published recommendations to US-based clinicians on integrating e-cigarettes into conversations with patients about the risks and benefits of pharmacologic treatments for smoking cessation. Notably, the group recommends that “patients should not be required to first try or fail an FDA-approved medication before using an e-cigarette for cessation because supporting cigarette cessation is the primary goal.” If a patient chooses e-cigarettes, they advise using products authorized for sale by the US Food and Drug Administration and counseling patients to completely substitute e-cigarettes for combustible cigarettes as quickly as possible.

Like combustible cigarettes, e-cigarettes appear to increase the risk of chronic respiratory conditions in adults. An FPIN Clinical Inquiry found several observational studies that associated e-cigarette use with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap syndrome. Nonetheless, the working group endorsed long-term e-cigarette use as a harm reduction strategy for maintaining complete abstinence from combustible cigarettes in patients who are unable to transition away from nicotine altogether.

**

This post first appeared on the AFP Community Blog.